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Abstract
Myasthenia gravis (MG) is an autoimmune disease characterized by the presence of autoantibodies, mainly against the
acetylcholine receptor (AChR). The mechanisms triggering and maintaining this chronic disease are unknown. MiRNAs are
regulatory molecules that play a key role in the immune system and are altered in many autoimmune diseases. The aim of
this study was to evaluate miRNA profiles in serum of 61 AChR MG patients. We studied serum from patients with early
onset MG (n = 22), late onset MG (n = 27) and thymoma (n = 12), to identify alterations in the specific subgroups. In a
discovery cohort, we analysed 381 miRNA arrays from 5 patients from each subgroup, and 5 healthy controls. The 15
patients had not received any treatment. We found 32 miRNAs in different levels in MG and analysed 8 of these in a
validation cohort that included 46 of the MG patients. MiR15b, miR122, miR-140-3p, miR185, miR192, miR20b and miR-885-
5p were in lower levels in MG patients than in controls. Our study suggests that different clinical phenotypes in MG share
common altered mechanisms in circulating miRNAs, with no additional contribution of the thymoma. MG treatment
intervention does not modify the profile of these miRNAs. Novel insights into the pathogenesis of MG can be reached by
the analysis of circulating miRNAs since some of these miRNAs have also been found low in MG peripheral mononuclear
cells, and have targets with important roles in B cell survival and antibody production.
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Introduction
Myasthenia gravis (MG) is an autoimmune disease leading to
fluctuating muscle weakness and fatigability. Patients with MG
have been reported to have autoantibodies to the acetylcholine
receptor (AChR), to MuSK or to LRP4 proteins [1,2,3]. Most MG
patients, however, have circulating antibodies to AChR [4]. These
antibodies are of the IgG subtype and their synthesis requires
interaction between activated T and B cells [5]. Suggested
mechanisms leading to autoantibody production include errors
in antigen presentation or recognition [6,7,8], tolerance against
self-antigens [9], and proliferation/apoptosis regulation of these
immune cells [10,11].
MG patients with AChR antibodies are clinically heterogeneous
[12]. Age at onset varies, and patients can be divided into early
onset MG (EOMG), when symptoms appear before 50 years of
age, or in late onset MG (LOMG), when they appear after 50
years [13]. Thymic involvement is also variable, more than 80% of
EOMG patients have thymic hyperplasia [14] and 10–15% of
MG patients have thymoma [15]. Thymectomy is used as a
therapeutical intervention in EOMG [16] and in patients with
thymoma. Response to treatment is also diverse. Most patients
respond to steroids or other immunesuppressors, but some patients
are refractory to standard therapy [15]. The heterogeneity is not
only clinical and therapeutic. It may also involve the AChR
antibody titers, which may be high or low independently of the
patient’s clinical status [17]. These findings suggest that the
pathogenic mechanisms involved in each patient subgroup are
different. No biomarkers are available, however, to predict such
heterogeneity.
MiRNAs are small, non-coding regulatory molecules that
modify gene expression by binding to the 39 untranslated region
of their target messenger RNAs [18]. These molecules are key in
several cellular functions, and changes in their expression patterns
have been associated with several diseases [19,20,21,22]. miRNAs
play a diverse role in the immune system, participating in immune
cell development, germinal center response, generation of Ig class-
switched plasma cells, and response to toll-like receptor stimulus
[23]. All of these mechanisms are potentially involved in the
development of AChR antibodies. MiRNA expression profiles
have been previously studied in peripheral blood mononuclear
cells of MG patients [24,25] and let-7c and miR320 have been
found downregulated. Functional studies have shown that these
two miRNAs can contribute to MG induction or progression by
regulating the expression of some cytokines. A recent study has
shown that miR146a is upregulated in patients, and it can be
regulating genes as CD40, CD80, TLR4 and NFkB [26].
Circulating miRNAs have been extensively studied from their
discovery [27,28], as they have been found altered in different
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pathological conditions [28,29,30,31]. In circulation, they are in
microvesicles released by cells [32,33,34] or in association with
proteins complexes [35,36]. and their presence in the blood has
been attributed to release by tissue injury [37] or shedding of cell
plasma membrane to the circulation [38]. Their origin is diverse
and they can be released by blood cells [39,40], organs of the body
[37,41,42,43,44] and tumors [45,46,47]. Their function seems to
be related with intercellular or iterorgan communication [38],
because microvesicles containing them can reach their target host
and accomplish their function [39,48,49]. Due to miRNA stability
in fresh or criopreserved samples [27,50] and their easy obtention
from blood, they can be easily studied, monitored and used as
biomarkers for diagnosis [51,52], prognosis [52,53], or treatment
[54,55]. However, serum miRNAs have not been studied in MG.
We studied miRNAs in serum from patients with AchR MG,
analyzing three subgroups: patients with EOMG, LOMG, and
thymoma. We identified 7 miRNAs with low levels in MG patients
when compared with healthy controls. These miRNAs low levels
were not modified by MG subgroup, steroid treatment or
thymectomy.
Materials and Methods
Ethics Statement
The study was approved by the Institutional Ethics Committee
at Hospital de la Santa Creu i Sant Pau and performed in
accordance with the Declaration of Helsinki for Human Research.
All participants gave written informed consent for inclusion.
Patient information
All patients with MG and AChR antibodies included in this
study were followed in our neurology unit. Healthy subjects were
used as controls.
Fifteen MG patients were selected for a discovery cohort: 5 early
onset myasthenia gravis (EOMG), 5 late onset myasthenia gravis
(LOMG) and 5 thymoma patients. We excluded patients with
other severe concomitant diseases. Serum from all patients was
collected before any immunotherapy was started and before
thymectomy in the case of patients with thymoma. Five healthy
subjects were used as controls. Epidemiological data are provided
in Table 1.
A validation cohort with 46 additional MG patients was used to
analyze miRNAs that showed different levels between MG
patients and controls. MG patients included 17 EOMG, 22
LOMG and 7 thymoma patients (Table 2). For this second
miRNA analysis, we included patients without treatment (n = 23),
patients with steroid treatment (n = 10), patients with steroid plus
other immunosuppressor treatment (n = 7), and patients with other
immunosuppressor treatment only (n = 6). We recorded whether
or not patients were thymectomyzed at the moment of sera
collection. Seventeen healthy controls were also analysed.
Sample collection
Serum samples were collected in BD Vacutainer SST tubes
(BD, New Jersey, NJ, EEUU). Tubes were inverted 5 times to mix
silicone and micronized silica particles that accelerate clotting
formation. Tubes were kept in vertical position for 30 minutes to
allow clot formation and centrifuged at 1300 g for 10 minutes. A
clear separation between serum specimens and clot was formed
and serum fractions were aliquoted and stored at 280uC until
used.
miRNA profiling
Total RNA was extracted using the mirVana PARIS kit
according to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA, USA). Reverse transcription was performed using
the TaqMan MicroRNA Reverse Transcription kit (Applied
Biosystems, Foster City, CA, USA) in combination with the
Megaplex RT human Primers Pool A (Invitrogen, Carslab, CA,
USA). For each sample, the Megaplex reverse transcription
product A was preamplified using the Megaplex PreAmp Primers
pool (Applied Biosystems, Foster City, CA, USA). The preampli-
fication product was loaded onto the Taqman array microfluidic
cards Human MicroRNA Array A panel v2.0, for the study of 381
mature miRNAs. Global miRNA profiling was performed by real-
time quantitative PCR on the 7900HT Fast Real Time PCR
System (Applied Biosystems). Individual assays were also studied:
miR15b, miR20b, miR122, miR-140-3p, miR-185, miR-192,
miR-375, miR-483-5p and miR885-5P. The assays were per-
formed in duplicate on the ABI 7900HT (Applied Biosystems, CA,
USA) and the relative levels were calculated using the 22DDCt
method.
Table 1. Subjects analyzed in the discovery cohort.
Early onset (EOMG) Age at onset Sex
33 M
41 M
34 F
36 F
31 F
Average 35
Late onset (LOMG) Age at onset Sex
78 M
81 M
83 M
83 F
79 F
Average 81
Thymoma Age at onset Sex
50 M
71 F
67 F
59 F
49 M
Average 59
Healthy subjects Age Sex
60 F
35 F
70 F
80 M
40 M
Average 57
M = male; F = female.
doi:10.1371/journal.pone.0091927.t001
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Data analysis
Data analysis was obtained using SDS 2.4 software (Applied
Biosystems). The baselines and thresholds were individually set up
for each miRNA using the RQ Manager 1.2.1 (Applied
Biosystems). To avoid inaccurate results, low-detected miRNAs
(Ct.34) were excluded from downstream analyses. Different types
of quality checks were done for Taqman array following the
methods developed by Heidi Dvinge (http://bioconductor.org/
packages/2.12/bioc/html/HTqPCR.html). For the normalization
we explored the possibility of using delta Ct method that is the
most widely used [56], and geometric mean method because it is
beneficial for miRNA studies [57]. After performing a Q-Q plot, a
boxplots figure, a density plot and a PCA plot for each method, we
observed that no significant differences were appreciated. Thus,
we decided to use the delta Ct approach because it is the most used
normalizing method. In order to normalize raw Ct values, we
computed the delta Ct values based on the mean of U6 snRNA,
miR-30b and miR-483-5p [58]. These three small RNAs showed
stability across the samples and a good detection levels (Ct,27),
two of the principal conditions for an appropriate endogenous
control. MiRNAs were removed from the analysis when they
showed more than 3 samples with ‘‘undetermined’’ or Ct values
.34, or when the standard deviation was below the 20 percentile
of all standard deviations. For the Taqman arrays, the analysis of
differentially miRNAs levels was based on a technique similar to
ANOVA specifically developed for microarray data analysis by
Smith et al. [59] that can also be applied to qPCR data. P-values
were adjusted for multiple comparisons following the false
discovery rate correction [60]. The selection criteria followed for
considering that microRNA levels were different between disease
and control sera was p adjusted value ,0.05. Namely, all the
miRNAs whose p values were ,0.05 after multiple comparison
correction by False Discovery Rate. In the case of individual assays
for miRNA analysis, the data was normalized only by miR483-5p.
Raw data of the Taqman arrays and the qPCR studies is provided
(Table S1). Mann-Whitney or Kruskall Wallis tests were used to
determine significant differences in miRNA individual analysis
(GraphPad Prism v5.0). In this case, the selection criteria followed
for considering that miRNA levels were different was p value
,0.05.
Results
Differential levels of miRNAs in the discovery cohort
After quality checks and filtering, 93 miRNAs were included in
the analysis. Statistical analysis showed that 32 miRNAs showed
different levels (p,0.05) between MG patients and healthy
controls. Figure 1 shows heatmap with unsupervised clustering
of delta Ct values of these 32 miRNAs.
When we compared the different subgroups of MG (EOMG,
LOMG or thymoma) with healthy controls, some miRNAs were in
different levels only in specific MG subgroups (Table S2). All these
miRNAs presented a fold change .2. In the EOMG subgroup,
miR518d was in high levels and let7g, miR-192, miR24, miR15b,
let7e, miR221, miR652, miR-345, miR20b, miR-140 and miR331
were in low levels. We observed low levels of miRNAs specific for
the LOMG subgroup: miR375, miR122, miR185, miR140-3p,
Table 2. MG patients studied in the validation cohort.
Early onset MG Age at onset Sex Treatment Thymectomy
22 F No Yes
42 F No No
28 F No No
20 F No No
11 F OI Yes
16 F No Yes
13 F No No
48 F Cort Yes
28 F Cort No
23 F Cort Yes
16 F OI Yes
40 M Cort No
12 F Cort + OI No
21 F No Yes
25 F Cort Yes
29 F Cort Yes
34 F No Yes
Average 25
Late onset MG Age at onset Sex Treatment Thymectomy
77 F No No
77 M No No
80 F No No
80 M No No
78 M No No
69 M No No
65 M No No
65 M OI Yes
59 M Cort + OI No
64 M OI No
78 F No No
73 M OI No
63 M No No
60 M No No
81 F No No
75 M No No
59 M Cort No
69 M OI No
53 M Cort + OI No
55 M Cort + OI No
74 F Cort No
53 M No No
Average 69
Thymoma MG Age at onset Sex Treatment Thymectomy
33 F Cort + OI Yes
46 M Cort Yes
33 M Cort + OI Yes
44 M No Yes
54 M Cort Yes
14 F Cort + OI Yes
62 F No No
Average 41
M = male; F = female; No = No treatment/No thymectomy; Cort =
corticosteroids; Other immunosuppressors = OI; Yes = Thymectomy.
doi:10.1371/journal.pone.0091927.t002
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miR-885-5p, miR486, miR324-3p and miR16. The subgroup of
thymoma showed no differences in miRNAs when compared with
healthy controls.
Analysis of the selected miRNAs in the validation cohort
Several miRNAs were selected for further analysis based on
their statistical significance in the analysis, and because they had
not been previously related to MG. For confirmation purposes we
chose 3 miRNAs from the EOMG subgroup: miR15b, miR20b,
miR-192; and 5 miRNAs from the LOMG subgroup: miR122,
miR-140-3p, miR-185, miR-375, and miR885-5P. These miRNAs
were analyzed in the validation cohort. Seven miRNAs show lower
levels in MG patients than in controls (Figure 2).
When considering MG subgroups (Figures 2), only miR15b was
found low in the three groups: EOMG, LOMG and thymoma.
For most miRNAs studied (miR122, miR140-3p, miR-185, miR-
192 and miR20b), only EOMG and LOMG showed differences
compared to controls. Levels in the thymoma group did not reach
statistical significance, but the overall trend of the data recapit-
Figure 1. Unsupervised HeatMap showing deltaCt values of the miRNA in differential levels between MG patients and controls in
the discovery cohort. Delta Ct value is the difference between Ct value of the target miRNA minus Ct value of the reference small RNAs. The scale
at top indicates high delta Ct values (in red shades) and low delta Ct values (in green shades). All miRNAs with a p adjusted value ,0.05 are shown.
Early onset MG (green), late onset MG (red), thymoma MG (blue) and healthy controls (purple).
doi:10.1371/journal.pone.0091927.g001
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ulated the results of the other MG subgroups. Low levels of
miR885-5p were only found in the LOMG.
Thymectomy and treatment effect in the differential
levels of miRNAs
Thymectomy is standard treatment for patients with thymoma
but it is also used as treatment in EOMG patients without
thymoma [12]. Seventeen patients in our validation cohort had
previously been thymectomised. We evaluated the effect of
thymectomy in miRNA levels and observed no differences
between patients with or without thymectomy (Figure 3). Twen-
ty-three patients in our validation cohort were also receiving
chronic immunosuppressive treatment. We classified patients as
untreated, treated with steroids, treated with other immunosup-
pressive agents, or treated with steroids and other immunosup-
pressive agents. We observe no differences in miRNA levels
between treated and untreated patients regardless of the treatment
(Figure 4).
Discussion
Our study describes the presence of a miRNA profile that is
common to all MG subgroups. We based our clinical phenotype
classification in three main groups: EOMG, LOMG and
thymoma. Fifteen patients were evaluated in a first attempt to
identify specific miRNAs between the different subgroups and
miR15b, miR122, miR-140-3p, miR185, miR192, miR20b, miR-
885-5p and miR-385 were selected for a second analysis in a
validation cohort of 46 patients. Although differences appeared in
our initial analysis, when studying the additional cohort, we did
not find significant differences. One of the studied miRNAs,
miR15b, was in low levels in all three subtypes of MG. EOMG
and LOMG subtypes shared deregulation of other 6 miRNAs.
The miRNA in thymoma patients was similar to that in the other
two subtypes, but it probably did not reach statistical significance
due to the small number of patients in this group. Our study shows
an alteration of the circulating levels of at least 7 miRNAs -
miR15b, miR122, miR-140-3p, miR185, miR192, miR20b and
miR-885-5p - found at low levels in MG patients.
In our attempt to identify specific miRNA profiles for each MG
subtype we did not find differences among subtypes. EOMG and
LOMG classificate two groups of MG patients based on the age of
onset, however, they differ in many other characteristics [61]. In
the case of EOMG patients there is intrathymic lymphoid follicles
and germinal centers [62], there are more women affected than
men [63], and some patients also develop other autoimmune
diseases [64]. In the case of LOMG, thymic abnormalities are
rarely found [65], patients are predominantly male, antibodies
against other proteins in the neuromuscular junction can also be
found [63], and there is an increase of incidence in the last years of
these patients [66]. These differences on clinical presentation are
also in line with some findings that support differences in their
underlying immune-mechanism [67,68]. Despite the MG diver-
sity, some authors suggest that MG is a single condition
constituting a continuous clinical spectrum with overlapping
features [65,69]. In line with these last findings, our study shows
that these two groups share alterations in their circulating miRNA
profile.
Circulating miRNAs can be used as biomarker for diagnosis of
different types of cancer [28,47]. In the case of the thymoma
subtype, we expected to find some effect in miRNA levels due to
the neoplastic process, but no differences were found when
compared with healthy controls. Serum might not be a good
sample to characterize thymus-derived miRNAs, either because its
contribution to blood miRNAs was minor or because thymus-
derived miRNAs were not included in our analysis.
The seven miRNAs with lower levels were not modified by
thymectomy or MG treatment. Some studies have reported that
steroids can modify the miRNA profile [70,71]. To avoid
treatment bias, the initial miRNA analysis was done in untreated
patients. In the validation cohort, we analyzed the effect of several
treatments. MiRNA levels in MG patients remained low,
regardless of the treatment. Interestingly, most of the patients
belonged to the untreated or steroid treated group, and steroids
did not modify the levels of the studied miRNAs. These results
may indicate that common clinical interventions do not target the
release of these circulating miRNAs in MG patients.
MiRNAs presence in circulation has been explained as a way of
intercellular communication [47,72]. The finding of a subset of
miRNAs with low abundance in circulation in serum MG can
indicate different things: lower release of these miRNA to
circulation or a higher uptake of these miRNAs by their targets.
Little is known about how this miRNAs reach and act in their
targets, but more studies address miRNAs cell release [38,39].
Blood cells are one of the contributors to the circulating miRNAs
[31,73]. Previous analysis in MG patients in peripheral blood
mononuclear cells (PBMCs) have defined profiles of differentially
expressed miRNAs compared to healthy population [24,25].
Although their studies focused on other miRNAs, three of the
miRNAs found in low levels in circulation in our MG patients -
miR15b, miR20b and miR185 - were also found in low levels in
PMBCs of MG patients in both analysis. Although a better
approach would be to analyze PBMCs and serum from the same
patients, these findings suggest that some of the miRNAs that we
have found in low levels in circulation proceed from PBMCs.
However, other cells should be contributing to the altered
circulating profile of MG, because miR122, miR140-3p,
miR192 and miR885-5p were not differentially expressed in
PBMCs.
MiRNA-15b and miR20b are two of the miRNAs found at
lower levels in MG patients. The genomic region that codes
miR15b is commonly affected in more than 50% of the patients
with chronic lymphocytic leukemia [74]. This miRNA functions as
a tumor suppressor by inhibiting the expression of B-cell
lymphoma-2 (BCL2) [75], and plays an important role in
controlling B cell homeostasis. BCL2 also has regulatory domains
for the inhibition of miR-20b [76]. BCL2 has been found to play
some role in MG pathology, being up-regulated in germinal
centers where autoreactive B cells normally undergo apoptosis
[77]. Other of the lower circulating miRNAs found in our MG
patients is miR-185. This miR is highly expressed in blood cells
and targets Bruton Tyrosine Kynase (BTK), an effector of the B
cell receptor signaling [78]. When B cells have low levels of
miR185, cells produce high titers of autoreactive antibodies and
lead to autoimmune features in mice. Although our findings are in
extracellular miRNAs, this three miRNAs have also been found in
lower levels in MG PBMCs [24,25], where they can have a role in
Figure 2. miR15b, miR122, miR140-3p, miR185, miR192, miR20b and miR885-5p show low levels in sera of MG patients. No
differences were found for miR375. Graphs show relative quantification of the miRNAs in the 3 MG subtypes; EOMG = early onset MG; late onset MG;
thymoma = thymoma MG; CTRL = healthy controls; *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0091927.g002
Serum miRNA Profiles in Myasthenia Gravis Patients
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e91927
Figure 3. Effect of thymectomy on miRNAs levels in the validation cohort. YES = thymectomyzed MG patient; NO = not thymectomyzed
MG patient.
doi:10.1371/journal.pone.0091927.g003
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MG pathogenesis by regulating key pathways in B cell survival and
autoantibody production.
MiR-122 is highly expressed in liver [76] and has an important
positive role in the regulation of hepatitis C virus replication [79].
Many studies propose miR-122 as a valuable circulating
biomarker for diagnosis and prognosis of different liver diseases
[80,81,82,83]. Although liver must be the main contributor to
serum miR-122, other tissues expressing this miRNA (brain, heart,
kidney, lung, ovary, testis and thymus) can also be participating
[37]. In addition, in in vitro reporter assays [84], miR-122 regulates
the nuclear factor of activated T cells calcium dependent
(NFATC1) and neuronal cell adhesion molecule 1 (NCAM1).
Both are molecules related with the immune system playing roles
in proliferation of T and B cells after antigen stimulation [85], and
regulation of natural killer cells and subpopulations of T cells
[86,87]. Further studies are needed to understand the role of
circulating miR-122 in MG.
Conclusions
In summary, we identified a set of 7 miRNAs that had lower
levels in serum of MG patients. Our findings support that (1)
EOMG and LOMG share a miRNA profile and therefore share
common altered mechanisms; (2) the neoplastic process of a
thymoma does not contribute to changes in the sera levels of the
studied miRNAs; (3) MG treatment intervention does not modify
this set of miRNAs; and (4) the analysis or circulating miRNAs
might provide insights into the pathogenesis of MG since some of
these miRNAs have also been found lower in peripheral
mononuclear cells, and have targets with important roles in B
cell survival and antibody production. Further studies in larger
cohorts of patients will be needed to determine whether these
miRNAs could be useful biomarkers in clinical prognosis or
response to therapy
Supporting Information
Table S1 Raw data for qPCR studies. This table is
composed of three worksheets: Taqman array microfluidic cards
Human MicroRNA Array A panel v2.0; individual analysis study
1; and iIndividual analysis study 2. A = early onset MG; B = late
onset MG; C = thymoma MG; E = healthy control; Ref sample =
same sample to perform relative quantification for all the plates.
(XLSX)
Table S2 Differential miRNA levels in the discovery
cohort. miRNAs showing differences in a specific subgroup of
MG are indicated in bold; Padj = P adjusted.
(XLSX)
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